An undesired effect of chemotherapy: Gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factorκb- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4

Journal of Biological Chemistry

Volumn 288, Issue 29, 2013, Pages 21197-21207

  Arora, Sumit ^a   Bhardwaj, Arun ^a   Singh, Seema ^a   Srivastava, Sanjeev K ^a   McClellan, Steven ^a   Nirodi, Chaitanya S ^a   Piazza, Gary A ^a   Grizzle, William E ^b   Owen, Laurie B ^a   Singh, Ajay P ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA-INDUCIBLE FACTOR 1; INVASIVENESS; NUCLEAR FACTORS; PANCREATIC CANCERS; REACTIVE OXYGEN; RESISTANCE MECHANISMS; THERAPEUTIC STRATEGY; UP-REGULATION;

CHEMOTHERAPY;

CELLS;

CHEMOKINE RECEPTOR CXCR4; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FRACTIONATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION;

CHROMATOGRAPHY; CXCR4; HYPOXIA-INDUCIBLE FACTOR (HIF); NF-ΚB; PANCREATIC CANCER; REACTIVE OXYGEN SPECIES (ROS);

CELL LINE, TUMOR; CELL MOVEMENT; DEOXYCYTIDINE; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASM INVASIVENESS; NF-KAPPA B; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; RECEPTORS, CXCR4; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84880555876     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.484576     Document Type: Article

References (42)

1. Long, J., Zhang, Y., Yu, X., Yang, J., LeBrun, D. G., Chen, C., Yao, Q., and Li, M. (2011) Overcoming drug resistance in pancreatic cancer. Expert. Opin. Ther. Targets 15, 817-828
2. Siegel, R., Naishadham, D., and Jemal, A. (2013) Cancer statistics, 2013. CA-Cancer J. Clin. 63, 11-30
3. Bardeesy, N., and DePinho, R. A. (2002) Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2, 897-909
4. Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., Mclntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., Frese, K. K., Denicola, G., Feig, C., Combs, C., Winter, S. P., Ireland-Zecchini, H., Reichelt, S., Howat, W. J., Chang, A., Dhara, M., Wang, L., Ruckert, F., Grutzmann, R., Pilarsky, C., Izeradjene, K., Hingorani, S. R., Huang, P., Davies, S. E., Plunkett, W., Egorin, M., Hruban, R. H., White-bread, N., McGovern, K., Adams, J., Iacobuzio-Donahue, C., Griffiths, J., and Tuveson, D. A. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324,1457-1461
5. Wang, Z., Li, Y., Ahmad, A., Banerjee, S., Azmi, A. S., Kong, D., and Sarkar, F. H. (2011) Pancreatic cancer. Understanding and overcoming chemore-sistance. Nat. Rev. Gastroenterol. Hepatol. 8, 27-33
6. Warsame, R., and Grothey, A. (2012) Treatment options for advanced pancreatic cancer. A review. Expert. Rev. Anticancer Ther. 12,1327-1336
7. Singh, S., Srivastava, S. K., Bhardwaj, A., Owen, L. B., and Singh, A. P. (2010) CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells. A novel target for therapy. Br. J. Cancer. 103, 1671-1679
8. Koshiba, T., Hosotani, R., Miyamoto, Y., Ida, J., Tsuji, S., Nakajima, S., Kawaguchi, M., Kobayashi, H., Doi, R., Hori, T., Fujii, N., and Imamura, M. (2000) Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer. A possible role for tumor progression. Clin. Cancer Res. 6, 3530-3535
9. Matsuo, Y., Ochi, N., Sawai, H., Yasuda, A., Takahashi, H., Funahashi, H., Takeyama, H., Tong, Z., and Guha, S. (2009) CXCL8/IL-8 and CXCL12/ SDF-1α co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int. J. Cancer. 124, 853-861
10. Teicher, B. A., and Fricker, S. P. (2010) CXCL12 (SDF-1)/CXCR4pathway in cancer. Clin. Cancer Res. 16, 2927-2931
11. Sun, X., Cheng, G., Hao, M., Zheng, J., Zhou, X., Zhang, J., Taichman, R. S., Pienta, K. J., and Wang, J. (2010) CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29, 709-722
12. Singh, A. P., Arora, S., Bhardwaj, A., Srivastava, S. K., Kadakia, M. P., Wang, B., Grizzle, W. E., Owen, L. B., and Singh, S. (2012) CXCL12/ CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κB. Implications for bidirectional tumor-stromal interactions. J. Biol. Chem. 287, 39115-39124
13. Bailey, J. M., Swanson, B. J., Hamada, T., Eggers, J. P., Singh, P. K., Caffery, T., Ouellette, M. M., and Hollingsworth, M. A. (2008) Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 14, 5995-6004
14. Arora, S., Bhardwaj, A., Srivastava, S. K., Singh, S., McClellan, S., Wang, B., and Singh, A. P. (2011) Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. PLoS ONE. 6, e21573
15. Donadelli, M., Costanzo, C., Beghelli, S., Scupoli, M. T., Dandrea, M., Bonora, A., Piacentini, P., Budillon, A., Caraglia, M., Scarpa, A., and Palmieri, M. (2007) Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim. Biophys. Acta 1773, 1095-1106
16. Trachootham, D., Lu, W., Ogasawara, M. A., Nilsa, R. D., and Huang, P. (2008) Redox regulation of cell survival. Antioxid. Redox. Signal. 10, 1343-1374
17. Oh, Y. S., Kim, H. Y., Song, I. C., Yun, H. J., Jo, D. Y., Kim, S., and Lee, H. J. (2012) Hypoxia induces CXCR4 expression and biological activity in gastric cancer cells through activation of hypoxia-inducible factor-1a. Oncol. Rep. 28, 2239 -2246
18. Sung, B., Jhurani, S., Ahn, K. S., Mastuo, Y., Yi, T., Guha, S., Liu, M., and Aggarwal, B. B. (2008) Zerumbone down-regulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells. Cancer Res. 68, 8938 - 8944
19. Park, K. R., Nam, D., Yun, H. M., Lee, S. G., Jang, H. J., Sethi, G., Cho, S. K., and Ahn, K. S. (2011) β-Caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation. CancerLett. 312,178-188
20. van Uden, P., Kenneth, N. S., and Rocha, S. (2008) Regulation of hypoxia-inducible factor-1a by NF-κB. Biochem. J. 412, 477-484
21. Xiao, H., Wang, J., Yuan, L., Xiao, C., Wang, Y., and Liu, X. (2013) Chicoric acid induces apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. J. Agric. Food Chem. 61, 1509-1520
22. Fruehauf, J. P., and Meyskens, F. L., Jr. (2007) Reactive oxygen species. A breath of life or death? Clin. Cancer Res. 13, 789-794
23. Armstrong, L., Hughes, O., Yung, S., Hyslop, L., Stewart, R., Wappler, I., Peters, H., Walter, T., Stojkovic, P., Evans, J., Stojkovic, M., and Lako, M. (2006) The role of PI3K/AKT, MAPK/ERK and NFκB signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. Hum. Mol. Genet. 15,1894-1913
24. Du, J., Xu, R., Hu, Z., Tian, Y., Zhu, Y., Gu, L., and Zhou, L. (2011) PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1αlpha expression in MCF-7 breast cancer cells. PLoS ONE. 6, e25213
25. Calvani, M., Comito, G., Giannoni, E., and Chiarugi, P. (2012) Time-dependent stabilization of hypoxia inducible factor-1a by different intracel-lular sources of reactive oxygen species. PLoS ONE 7, e38388
26. Jung, S. N., Yang, W. K., Kim, J., Kim, H. S., Kim, E. J., Yun, H., Park, H., Kim, S. S., Choe, W., Kang, I., and Ha, J. (2008) Reactive oxygen species stabilize hypoxia-inducible factor-1 a protein and stimulate transcrip-tional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. Carcinogenesis 29, 713-721
27. Maréchal, R., Demetter, P., Nagy, N., Berton, A., Decaestecker, C., Polus, M., Closset, J., Devière, J., Salmon, I., and Van Laethem, J. L. (2009) High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br. J. Cancer 100, 1444 -1451
28. Thomas, R. M., Kim, J., Revelo-Penafiel, M. P., Angel, R., Dawson, D. W., and Lowy, A. M. (2008) The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia. Gut 57, 1555-1560
29. Marchesi, F., Monti, P., Leone, B. E., Zerbi, A., Vecchi, A., Piemonti, L., Mantovani, A., and Allavena, P. (2004) Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 64, 8420-8427
30. Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., and Heeschen, C. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323
31. Voutsadakis, I. A. (2011) Molecular predictors of gemcitabine response in pancreatic cancer. World J. Gastrointest Oncol. 3, 153-164
32. Wong, A., Soo, R. A., Yong, W. P., and Innocenti, F. (2009) Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab. Rev. 41, 77-88
33. Yokoi, K., and Fidler, I. J. (2004) Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin. Cancer Res. 10, 2299-2306
34. Zhao, Y., Shen, S., Guo, J., Chen, H., Greenblatt, D. Y., Kleeff, J., Liao, Q., Chen, G., Friess, H., and Leung, P. S. (2006) Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J. Surg. Res. 136, 325-335
35. Fryer, R. A., Barlett, B., Galustian, C., and Dalgleish, A. G. (2011) Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensi-tisation by the iMiD lenalidomide. Anticancer Res. 31, 3747-3756
36. Madrid, L. V., Wang, C. Y., Guttridge, D. C., Schottelius, A. J., Baldwin, A. S., Jr., and Mayo, M. W. (2000) Akt suppresses apoptosis bystimulating the transactivation potential of the RelA/p65 subunit of NF-κB. Mol. Cell. Biol. 20,1626-1638
37. Jiang, B., Xu, S., Hou, X., Pimentel, D. R., Brecher, P., and Cohen, R. A. (2004) Temporal control of NF-κB activation by ERK differentially regulates interleukin-1β-induced gene expression. J. Biol. Chem. 279, 1323-1329
38. Wei, Y. Y., Chen, Y. J., Hsiao, Y. C., Huang, Y. C., Lai, T. H., and Tang, C. H. (2008) Osteoblasts-derived TGF-β1 enhance motility and integrin up-regulation through Akt, ERK, and NF-κB-dependent pathway in human breast cancer cells. Mol. Carcinog. 47, 526-537
39. Wu, C. J., Wang, Y. H., Lin, C. J., Chen, H. H., and Chen, Y. J. (2011) Tetrandrine down-regulates ERK/NF-κB signaling and inhibits activation of mesangial cells. Toxicol. In Vitro 25, 1834-1840
40. Chua, Y. L., Dufour, E., Dassa, E. P., Rustin, P., Jacobs, H. T., Taylor, C. T., and Hagen, T. (2010) Stabilization of hypoxia-inducible factor-1a protein in hypoxia occurs independently of mitochondrial reactive oxygen species production. J.Biol. Chem. 285, 31277-31284
41. Bonello, S., Zahringer, C., BelAiba, R. S., Djordjevic, T., Hess, J., Michiels, C., Kietzmann, T., and Gorlach, A. (2007) Reactive oxygen species activate the HIF-1α promoter via a functional NFκB site. Arterioscler. Thromb. Vasc. Biol. 27, 755-761
42. Sun, H. L., Liu, Y. N., Huang, Y. T., Pan, S. L., Huang, D. Y., Guh, J. H., Lee, F. Y., Kuo, S. C., and Teng, C. M. (2007) YC-1 inhibits HIF-1 expression in prostate cancer cells. Contribution of Akt/NF-κB signaling to HIF-1α accumulation during hypoxia. Oncogene. 26, 3941-3951